By VETTAPHARMA reporter: NATCO Pharma Limited has received approval from the Central Drug Standard Control Organization (CDSCO) to manufacture and market generic Semaglutide Injection in India, the company announced on February 14, 2026.
NATCO stated that it plans to launch the product in the Indian market in March 2026.
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, to be used as an adjunct to diet and exercise. The approval allows NATCO to introduce a generic injectable version of the therapy in India.
NATCO Pharma Limited is listed on the Bombay Stock Exchange (BSE: 524816) and the National Stock Exchange of India (NSE: NATCOPHARM). The company did not disclose pricing, commercial strategy, or revenue projections in its announcement. However, the news led to over 10% jump in NATCO Pharma’s share price.
The approval could intensify competition in India’s GLP-1 diabetes therapy segment, particularly affecting companies marketing branded semaglutide products. Globally, semaglutide is marketed by Novo Nordisk under brand names such as Ozempic and Rybelsus. The entry of a generic injectable version in India may place pricing and market share pressure on the originator product in the domestic market.
Additionally, broader competitive dynamics in the GLP-1 segment — which includes products from companies such as Eli Lilly in the incretin-based diabetes treatment space, Mounjaro/Yurpeak — could become more aggressive as more domestic manufacturers enter the category.
With a planned launch in March 2026, NATCO’s market entry may increase access to semaglutide therapy while potentially reshaping pricing competition within India’s growing type 2 diabetes treatment market.
Source credit:
- NATCO Pharma Limited. (2026, February 14). NATCO receives approval from Central Drug Standard Control Organisation (CDSCO) for Semaglutide in India. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
